Jim Cramer breaks down the top 10 market-moving events for Tuesday, including the highly anticipated IPO prospectus of AI firm Anthropic and OpenAI’s developer day. Investors will also be watching Boeing’s stability after a software glitch and certification delay, and the increased sales potential for Johnson & Johnson’s new psoriasis pill, Icotyde.
The market is also keeping an eye on Iran’s economic situation impacting oil prices, Oura’s postponed IPO, Meta’s enterprise ambitions, Netflix’s upgrade, and the massive buyback plan by Nvidia. Hinge Health emerges as a promising healthcare story with a positive outlook from BofA.
Get ready for a busy Tuesday in the stock market as Jim Cramer highlights the top 10 critical factors investors should be watching. From the looming artificial intelligence IPOs to potential turbulence for aerospace giants and the promising outlook for a new pharmaceutical drug, this list is packed with insights.
1. Iran's Economic Strain and Crude Oil Prices: Keep an eye on Iran's economic situation, reportedly struggling under an oil embargo. This development, amplified by The Wall Street Journal, is contributing to lower crude prices and calm bond yields. This combination is typically supportive of the stock market, signaling a potential higher open for the S&P 500.
2. Anthropic's Impending IPO: Reuters has obtained a glimpse of Anthropic's S-1 filing, revealing the AI startup's ambitious plans and potential risks. The document warns of "existential risk to humanity" due to artificial intelligence, yet highlights impressive growth, with revenue growing 12-fold last year. The company anticipates spending $518 billion on cloud computing and AI infrastructure in the coming years, with an IPO expected in November.
3. OpenAI's Developer Day and GPT-6.1 Astra: OpenAI is holding its developer day today. Notably, the ChatGPT creator has decided to delay the release of its new model, GPT-6.1 Astra, citing the need for stronger safeguards. The model reportedly wasn't performing well enough on "alignment" (safe behavior) and "scope authorization" (adhering to permissions), following recent discussions on AI safety.
4. Oura Postpones IPO: Smart ring maker Oura has postponed its Nasdaq initial public offering, citing "uncertainty in the IPO market" despite strong demand. This news comes as the Nasdaq 100 remains close to its record high. The company had aimed to raise $2.2 billion, with reports indicating the deal was four times oversubscribed, making the postponement a disappointing development.
5. Meta's Enterprise Push: Investors should start viewing Meta not just as a consumer company but also as a formidable enterprise player. The power of its new Muse agent could drive significant multiple expansion for the stock. Following its move to hire MongoDB's CEO to spearhead its enterprise efforts, Meta has launched Muse for Small Business, leveraging its existing base of 200 million small businesses. Meta President Dina Powell McCormick will discuss this on "Mad Money" tonight.
6. Deutsche Bank Upgrades Netflix: A significant call to watch is Deutsche Bank's upgrade of Netflix to a "buy" rating from "hold." The stock has underperformed significantly since last summer. Deutsche Bank believes concerns about U.S. engagement trends are exaggerated, especially given Netflix's international growth and untapped overseas potential. The firm is also positive on Netflix's platform expansion into podcasts, video games, and other distribution partnerships.
7. Boeing's Credibility Concerns: Can Boeing regain its footing today after yesterday's sell-off triggered by a software glitch disclosure and a delay in the 737 Max 10 certification? The FAA is investigating the glitch as a potential safety issue. While Bank of America suggests the cash flow impact of the Max 10 delay is manageable, concerns are growing about Boeing's credibility. Cramer advises waiting until the stock reaches $180 to buy more, noting the general weakness in the aerospace sector.
8. Johnson & Johnson's Icotyde Potential: BofA has increased its price target for Johnson & Johnson to $278 from $263, maintaining a neutral rating ahead of third-quarter earnings. Analysts have raised their long-term sales estimates for Icotyde, J&J's new psoriasis pill, to $4.5 billion from $2.4 billion, with expectations for further indications. Cramer believes the peak sales could be much higher.
9. Nvidia's Buyback Power: Nvidia is showing slight gains, aiming to build on yesterday's advance following a massive $235 billion buyback announcement. Indications suggest these repurchases will be active, potentially altering the stock's trajectory in a manner similar to Apple's capital allocation plan that retired a significant portion of its stock.
10. Hinge Health's Healthcare Promise: BofA has initiated coverage on Hinge Health with a "buy" rating and a $110 price target, suggesting 19% upside. Analysts see multiple growth avenues for the digital physical therapy company, including new product adoption and increased member participation. Cramer expresses strong confidence in the company, noting CEO Daniel Perez's previous appearances on "Mad Money."
